MARKET

FLXN

FLXN

Flexion
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.12
+1.36
+11.56%
After Hours: 13.12 0 0.00% 16:00 07/14 EDT
OPEN
12.04
PREV CLOSE
11.76
HIGH
13.14
LOW
11.52
VOLUME
1.02M
TURNOVER
--
52 WEEK HIGH
22.98
52 WEEK LOW
5.01
MARKET CAP
627.05M
P/E (TTM)
-3.4577
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average FLXN stock price target is 21.89 with a high estimate of 35.00 and a low estimate of 17.00.

EPS

FLXN News

More
Flexion Therapeutics Sees Prelim. Q2 ZILRETTA Net Sales $15.4M
Benzinga · 9h ago
Flexion Therapeutics Announces Preliminary Second-Quarter 2020 ZILRETTA® Net Sales
* Company reported ZILRETTA (triamcinolone acetonide extended-release injectable suspension) preliminary net sales of $15.4 million in the second quarter * Demand for ZILRETTA from healthcare providers increased month-over-month throughout the second quarte
GlobeNewswire · 9h ago
Flexion Therapeutics (FLXN) Upgraded to Buy: What Does It Mean for the Stock?
Flexion Therapeutics (FLXN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 6d ago
Flexion Therapeutics, Inc. (NASDAQ:FLXN): When Will It Breakeven?
Simply Wall St. · 07/02 13:30
Here’s What Hedge Funds Think About Flexion Therapeutics Inc (FLXN)
In this article you are going to find out whether hedge funds think Flexion Therapeutics Inc (NASDAQ:FLXN) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have
Insider Monkey · 06/27 17:20
Benzinga's Top Upgrades, Downgrades For June 25, 2020
Benzinga · 06/25 15:10
HC Wainwright & Co. Initiates Coverage On Flexion Therapeutics with Buy Rating, Announces Price Target of $25
HC Wainwright & Co. initiates coverage on Flexion Therapeutics (NASDAQ:FLXN) with a Buy rating and announces Price Target of $25.
Benzinga · 06/25 10:47
Flexion Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
GlobeNewswire · 06/16 21:30

Industry

Biotechnology & Medical Research
+2.53%
Pharmaceuticals & Medical Research
+1.66%

Hot Stocks

Symbol
Price
%Change

About FLXN

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
More

Webull offers kinds of Flexion Therapeutics Inc stock information, including NASDAQ:FLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FLXN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FLXN stock methods without spending real money on the virtual paper trading platform.